MHLW Decides On Use And Dose For Methotrexate And Botox
This article was originally published in PharmAsia News
Japan's Ministry of Health, Labor and Welfare's Panel on Drugs to Children approved a working group paper on the use and dosage of two drugs: MTX (methotrexate) 2 mg manufactured by Wyeth and imported by Takeda, and GlaxoSmithKline's Botox (botulinum toxin type A). The recommended dose for MTX is 4 mg-10 mg within a week, and for Botox is 4 units per kilogram of a patient's weight, and with an administration interval of 3 month and maximum dose of 200 units. MTX treats juvenile idiopathic arthritis, a whole body chronic infection usually occuring in childhood. Botox treats equinus foot, a deformity associated with cerebral palsy. The panel will report the recommendations to MHLW's Food and Drug Council and request the companies to change the applications accordingly. (Click for more-Japanese language
You may also be interested in...
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.
Wholesalers are given three more years to set up electronic systems to verify saleable returns under another reprieve from the FDA. Yet the reprieve does not extend to manufacturers, who must respond within 24 hours to wholesalers’ requests to manually verify that a returned product is not suspect.
Agency explains how it will model vaccine authorization process on its licensing process for matters like inspections and lot release.